« Back
Home /
Perifosine

Perifosine

Item no.	M1823-200mg
Manufacturer	AbMole
CASRN	157716-52-4
Amount	200mg
Category	Oncology Food Safety Drugs Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	>99%
Citations	Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Richardson PG, et al . Expert Opin Drug Metab Toxicol. 2012 May,8(5):623-33. PMID: 22512706 . Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-kappaB signaling pathway in a human breast cancer cell line. Lin X, et al . Neoplasma. 2012,59(3):248-56. PMID: 22329846 . Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. Richardson PG, et al . J Clin Oncol. 2011 Nov 10,29(32):4243-9. PMID: 21990396 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	KRX-0401, NKA17
Similar products	Perifosine, KRX-0401, NKA17
Available
Target Information	Akt
Molecular Weight	461, 66
Solubility	Water 50 mg/mL
Bioactivity information	Perifosine is an orally active Akt inhibitor, the antiproliferative properties of Perifosine with an IC50 of 0.6–8.9 µM.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1823-200mg-safety-datasheet.pdf